Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use EPCLUSA safely and effectively. See full prescribing information for EPCLUSA. EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use EPCLUSA® (sofosbuvir and velpatasvir) oral pellets Initial U.S. Approval: 2016
Medication labelWhy this: Advisory · dailymed-prescription
EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2, 2.3, 2.4) and Clinical Studies (14)]: without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.
- generic_name
- velpatasvir and sofosbuvir
- product_names
- Velpatasvir and Sofosbuvir
- ndc
- 61958-2201, 61958-2201-1, 61958-2203, 61958-2203-1, 61958-2204, 61958-2204-1, 61958-2205, 61958-2205-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en